Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest Draft Of Rep. Dingell’s Global Drug Safety Bill Would Exempt Small Firms From Inspection Fees

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA would have flexibility to set inspection schedules; committee may use bill to address FDA executive bonuses

You may also be interested in...



Globalization Bill Creates Fees For Generic Pre-approval Inspections

A system for assessing fees for generic drug applicants to pay for pre-approval inspections is included in the 1FDA Globalization Act introduced in the House Jan. 28

Globalization Bill Creates Fees For Generic Pre-approval Inspections

A system for assessing fees for generic drug applicants to pay for pre-approval inspections is included in the 1FDA Globalization Act introduced in the House Jan. 28

FDA Should Be Allowed To Schedule Foreign Inspections Based On Risk – CDER’s Woodcock

“Risk-based” may be code for doing the minimum because of underfunding, Rep. Dingell says.

Related Content

Topics

UsernamePublicRestriction

Register

PS068154

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel